Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZNF710 antisense RNA 1 (ZNF710-AS1)
- Target
- ZNF710-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Other
01
Overview
ZNF710 antisense RNA 1 (ZNF710-AS1) is a long non-coding RNA transcribed antisense to the ZNF710 gene. It is mainly cytoplasmic and functions as a regulator of gene expression, including its sense partner ZNF710. ZNF710-AS1 is implicated in oncogenesis, with demonstrated roles in promoting cell proliferation, inhibiting apoptosis, and facilitating metastasis, notably in clear cell renal cell carcinoma and gastric cancer[1][3][4]. Lower expression of ZNF710-AS1 is linked to better prognosis and increased immune infiltration in tumors, while higher levels are associated with worse clinical outcomes and may influence response to chemotherapy[4]. It is under investigation as a potential prognostic biomarker and candidate therapeutic target in oncology.
- Other names
- ZNF710-AS1ENST00000558334ZNF710 antisense RNA 1-201ZNF710-AS1-201ZNF710-AS1-202
02
Mechanism of action
Not a direct drug target, but expression levels modulate chemotherapy sensitivity and are linked to cancer progression and immune infiltration[4].
03
Biological functions
Regulation of gene expressionRegulation of cell proliferationInhibition of apoptosisModulation of tumor immune microenvironmentFacilitation of cancer cell metastasis and invasion
04
Disease associations
CancerRenal cell carcinomaGastric cancer
05
Safety considerations
Potential risks relate to modulation of cell proliferation and survival; therapeutic targeting must consider possible effects on normal cell functions.As with other lncRNA targets, off-target or systemic effects remain a concern in translational or therapeutic contexts.
06
Interacting drugs
5-fluorouracil
5 more in the full profile.
07
Biomarkers
Prognostic biomarker for gastric cancer outcome[4]Correlates with clinical stage, tumor size, and pathological grade in clear cell renal cell carcinoma[1][3]May inform drug response prediction in gastric cancer[4]
Beyond the preview
Go deeper on ZNF710 antisense RNA 1 (ZNF710-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZNF710 antisense RNA 1 (ZNF710-AS1).